- Home
- JSPR vs IPSC Comparison
JSPR vs IPSC Comparison
Compare JSPR & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- IPSC
- Stock Information
- Founded
- JSPR 2018
- IPSC 2019
- Country
- JSPR United States
- IPSC United States
- Employees
- JSPR 64
- IPSC N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- JSPR Health Care
- IPSC Health Care
- Exchange
- JSPR Nasdaq
- IPSC Nasdaq
- Market Cap
- JSPR 47.6M
- IPSC 42.2M
- IPO Year
- JSPR N/A
- IPSC 2021
- Fundamental
- Price
- JSPR $2.86
- IPSC $0.56
- Analyst Decision
- JSPR Buy
- IPSC Strong Buy
- Analyst Count
- JSPR 12
- IPSC 5
- Target Price
- JSPR $30.78
- IPSC $3.33
- AVG Volume (30 Days)
- JSPR 293.2K
- IPSC 974.1K
- Earning Date
- JSPR 08-13-2025
- IPSC 08-14-2025
- Dividend Yield
- JSPR N/A
- IPSC N/A
- EPS Growth
- JSPR N/A
- IPSC N/A
- EPS
- JSPR N/A
- IPSC N/A
- Revenue
- JSPR N/A
- IPSC $114,128,000.00
- Revenue This Year
- JSPR N/A
- IPSC $1,590.09
- Revenue Next Year
- JSPR N/A
- IPSC N/A
- P/E Ratio
- JSPR N/A
- IPSC N/A
- Revenue Growth
- JSPR N/A
- IPSC 5491.77
- 52 Week Low
- JSPR $2.27
- IPSC $0.34
- 52 Week High
- JSPR $26.05
- IPSC $2.05
- Technical
- Relative Strength Index (RSI)
- JSPR 42.31
- IPSC 51.07
- Support Level
- JSPR $2.90
- IPSC $0.48
- Resistance Level
- JSPR $3.14
- IPSC $0.59
- Average True Range (ATR)
- JSPR 0.20
- IPSC 0.04
- MACD
- JSPR 0.09
- IPSC 0.00
- Stochastic Oscillator
- JSPR 71.03
- IPSC 74.00
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.